Wells Fargo Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Neurocrine Biosciences (NBIX) and increased the price target from $127 to $140.
February 08, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Neurocrine Biosciences and raised the price target from $127 to $140.
The increase in price target by a reputable analyst like Mohit Bansal from Wells Fargo suggests a positive outlook on Neurocrine Biosciences' stock. This adjustment reflects an expectation of stronger performance or favorable market conditions for NBIX, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90